MA34480B1 - Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires - Google Patents

Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires

Info

Publication number
MA34480B1
MA34480B1 MA35677A MA35677A MA34480B1 MA 34480 B1 MA34480 B1 MA 34480B1 MA 35677 A MA35677 A MA 35677A MA 35677 A MA35677 A MA 35677A MA 34480 B1 MA34480 B1 MA 34480B1
Authority
MA
Morocco
Prior art keywords
docosahexanoate
panthenyl
treating
cardiovascular diseases
preventing cardiovascular
Prior art date
Application number
MA35677A
Other languages
English (en)
Inventor
Frederique Lantoine-Adam
Robert Letienne
Elisabeth Dupont-Passelaigue
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA34480B1 publication Critical patent/MA34480B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne un docosahexanoate de panthényle répondant à la formule suivante : Elle concerne également un procédé pour le préparer et une composition pharmaceutique le contenant, ainsi que son utilisation pour traiter ou prévenir les maladies cardiovasculaires, en particulier, la fibrillation atriale.
MA35677A 2010-08-11 2011-08-11 Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires MA34480B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1056560A FR2963790B1 (fr) 2010-08-11 2010-08-11 Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
PCT/EP2011/063854 WO2012020094A1 (fr) 2010-08-11 2011-08-11 Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires

Publications (1)

Publication Number Publication Date
MA34480B1 true MA34480B1 (fr) 2013-08-01

Family

ID=43754935

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35677A MA34480B1 (fr) 2010-08-11 2011-08-11 Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires

Country Status (28)

Country Link
US (2) US20130137768A1 (fr)
EP (1) EP2603486B1 (fr)
JP (1) JP5960695B2 (fr)
KR (1) KR20140031830A (fr)
CN (1) CN103025707B (fr)
AR (1) AR082594A1 (fr)
AU (1) AU2011288410B2 (fr)
BR (1) BR112013003149A2 (fr)
CA (1) CA2806154A1 (fr)
CY (1) CY1116088T1 (fr)
DK (1) DK2603486T3 (fr)
ES (1) ES2531437T3 (fr)
FR (1) FR2963790B1 (fr)
HR (1) HRP20150265T1 (fr)
HU (1) HUE024560T2 (fr)
IL (1) IL224632A (fr)
MA (1) MA34480B1 (fr)
MX (1) MX2013001506A (fr)
MY (1) MY166065A (fr)
NZ (1) NZ607836A (fr)
PL (1) PL2603486T3 (fr)
PT (1) PT2603486E (fr)
RS (1) RS53896B1 (fr)
RU (1) RU2593203C2 (fr)
SI (1) SI2603486T1 (fr)
TW (1) TWI555528B (fr)
UA (1) UA109551C2 (fr)
WO (1) WO2012020094A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011014386A1 (de) * 2011-03-11 2012-09-13 Hemoteq Ag Endoprothese mit einer Wirkstoffbeschichtung
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
PL3176164T3 (pl) 2014-07-30 2020-05-18 Aetas Pharma Co. Ltd. Izomer optyczny pochodnej 1-tlenku 1,4-benzotiazepiny oraz farmaceutyczna kompozycja wytworzona z jego użyciem

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR955612A (fr) 1950-01-18
NL133049C (fr) * 1966-02-24
ITMI20022511A1 (it) 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
FR2902659A1 (fr) * 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale

Also Published As

Publication number Publication date
RU2593203C2 (ru) 2016-08-10
AU2011288410A1 (en) 2013-03-21
AU2011288410B2 (en) 2014-05-22
TWI555528B (zh) 2016-11-01
ES2531437T3 (es) 2015-03-16
HK1180298A1 (en) 2013-10-18
JP5960695B2 (ja) 2016-08-02
US20130137768A1 (en) 2013-05-30
EP2603486A1 (fr) 2013-06-19
EP2603486B1 (fr) 2014-12-17
DK2603486T3 (en) 2015-03-02
MY166065A (en) 2018-05-23
RU2013110131A (ru) 2014-09-20
CN103025707A (zh) 2013-04-03
UA109551C2 (uk) 2015-09-10
HUE024560T2 (hu) 2016-02-29
FR2963790A1 (fr) 2012-02-17
AR082594A1 (es) 2012-12-19
CN103025707B (zh) 2015-04-29
MX2013001506A (es) 2013-02-27
JP2013538197A (ja) 2013-10-10
PL2603486T3 (pl) 2015-05-29
RS53896B1 (sr) 2015-08-31
TW201208672A (en) 2012-03-01
KR20140031830A (ko) 2014-03-13
FR2963790B1 (fr) 2012-09-28
HRP20150265T1 (hr) 2015-04-10
US20150291507A1 (en) 2015-10-15
BR112013003149A2 (pt) 2017-03-28
WO2012020094A1 (fr) 2012-02-16
CY1116088T1 (el) 2017-02-08
NZ607836A (en) 2014-12-24
PT2603486E (pt) 2015-02-18
IL224632A (en) 2016-12-29
CA2806154A1 (fr) 2012-02-16
SI2603486T1 (sl) 2015-04-30

Similar Documents

Publication Publication Date Title
MA31167B1 (fr) Inhibiteurs de l'activite de akt
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
WO2012088266A3 (fr) Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
MX2013004491A (es) Boronatos como inhibidores de arginasa.
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
WO2015031564A3 (fr) Composés de la série des 1h-benzo[d]imidazoles substitués à titre d'inhibiteurs de déméthylase 1 spécifique de la lysine (lsd1)
MX2008001614A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
MA38393B1 (fr) Composés hétéroaryle et utilisations associées
MY203474A (en) Substituted tricyclic compounds as fgfr inhibitors
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
UA107783C2 (en) Isoindoline compounds for use in treating cancer
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
EA201491496A1 (ru) Ингибиторы c-концевого домена hsp90
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
PH12014501176A1 (en) Anticoagulant reversal agents
EA201591180A1 (ru) Составы ингибитора lfa-1